- Charles River Laboratories and NUS Medicine have announced a high-quality plasmid DNA development and manufacturing agreement.
Charles River Laboratories, a provider of products and services to help expedite the discovery, early-stage development and safe manufacture of novel drugs and therapeutics, has announced a high-quality (HQ) plasmid DNA development and manufacturing agreement with the National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine).
NUS Medicine, a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, will utilise Charles River’s market-leading contract development and manufacturing organisation (CDMO) expertise in HQ and GMP-compliant plasmid DNA. This serves as a critical starting material for its engineered stem cell cancer therapy and builds on a historic provision of research-grade plasmid.
The collaboration will allow NUS Medicine to access Charles River’s center of excellence and established manufacturing platform, eXpDNA™. This comes as Charles River has significantly expanded its cell and gene therapy portfolio in recent years to streamline complex supply chains and meet growing demand for plasmid DNA, viral vector, and cell therapy services.
Combined with the Company’s legacy testing capabilities, Charles River offers an industry-leading “concept to cure” advanced therapeutic solution. This is a significant step forward in the field of stem cell biology and therapy, and it underscores the importance of collaboration in advancing medical research and development.
“We are thrilled to continue our work with NUS Medicine and support their important work developing engineered stem cells for cancer therapy. Charles River has had decades of success manufacturing, and reliably delivering plasmid DNA as both a critical starting material and drug product, helping to safeguard our customer programs,” said Kerstin Dolph, Corporate Senior Vice President, Biologics Solutions, Charles River.
Overview of outsourcing trends 
